Pfizer's (NYSE:PFE) stock up by 7.7% over the past three months. However, we decided to study the company's mixed-bag of ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer: Performance Is Improving, But Secular Issues Persist (Rating Upgrade) Aug. 23, 2024 4:29 AM ET Pfizer Inc. (PFE) Stock , PFE:CA Stock PFE , PFE:CA 17 Comments 3 Likes KM Capital ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Firstly, let us look at Pfizer’s stock performance in recent years. PFE stock has faced a decline of 15% from levels of $35 in early January 2021 to around $30 now, vs. an increase of about 45% ...

Pfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis.

Pfizer is now more focused on innovative drugs and vaccines, analyst says Last Updated: Feb. 4, 2025 at 12:58 p.m. ET First Published: Feb. 4, 2025 at 7:09 a.m. ET Share ...